Nanni Schmitt

Nanni Schmitt

Auto-generated profile, based on publicly available information

Nanni Schmitt

Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JJJohann-Christoph Jann
Johann-Christoph Jann
MMMaximilian Mossner
Maximilian Mossner
VRVladimir Riabov
Vladimir Riabov
EAEva Altrock
Eva Altrock
NSNanni Schmitt
Nanni Schmitt
DNDaniel Nowak
Daniel Nowak
The bone marrow (BM) stroma in myeloid neoplasms is altered and it is hypothesized that this cell compartment may also harbor clonal somatically acquired mutations. By exome sequencing of in vitro expanded mesenchymal stromal cells (MSCs) from n = 98 patients with myelodysplastic syndrome (MDS) and n = 28 healthy controls we show that these cells accumulate recurrent mutations in genes such as ZFX (n = 8/98), RANK (n = 5/98), and others. MDS derived MSCs display higher mutational burdens, increased replicative stress, senescence, inflammatory gene expression, and distinct mutational signatures as compared to healthy MSCs. However, validation experiments in serial culture passages, chronological BM aspirations and backtracking of high confidence mutations by re-sequencing primary sorted MDS MSCs indicate that the discovered mutations are secondary to in vitro expansion but not present in primary BM. Thus, we here report that there is no evidence for clonal mutations in the BM stroma of MDS patients.

21 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
NSNanni Schmitt
Nanni Schmitt
JSJana-Julia Siegler
Jana-Julia Siegler
ABAlexandra Beck
Alexandra Beck
TMThomas Müller
Thomas Müller
IKIzabela Kozlowska
Izabela Kozlowska
DNDaniel Nowak
Daniel Nowak
Strategies targeting leukemic stem and progenitor cells (LSPCs) are needed for durable remissions in acute myeloid leukemia (AML) and high-risk myelodysplastic neoplasms (MDS). While CD123 constitutes a promising target on LSPCs and leukemic blasts, previous CD123-targeting approaches showed limited efficacy and challenging safety profiles. Here, we describe the preclinical efficacy and safety of the bispecific CD123/CD16A innate cell engager “AFM28”, demonstrating superior activity against AML and MDS patient-derived LSPCs and blasts in vitro compared to an Fc-enhanced CD123-targeting antibody, especially towards CD123low and/or CD64+ leukemic cells. AFM28 induces autologous anti-leukemic activity in fresh AML whole blood cultures, demonstrating its potential to enhance NK cell function from AML patients. Responsiveness can be further enhanced by allogeneic NK cell addition. Anti-leukemic activity of AFM28 is confirmed in xenograft mouse models. In addition, AFM28 is well tolerated and demonstrates pharmacodynamic activity in cynomolgus monkeys. Altogether, our results indicate that AFM28 has the potential to reduce relapse-inducing residual disease and promote long-term remissions for patients with AML and MDS with a favorable safety profile.

17 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
QXQingyu Xu
Qingyu Xu
ASAlexander Streuer
Alexander Streuer
JJJohann-Christoph Jann
Johann-Christoph Jann
EAEva Altrock
Eva Altrock
NSNanni Schmitt
Nanni Schmitt
DNDaniel Nowak
Daniel Nowak
Limited response rates and frequent relapses during standard of care with hypomethylating agents in myelodysplastic neoplasms (MN) require urgent improvement of this treatment indication. Here, by combining 5-azacytidine (5-AZA) with the pan-lysyl oxidase inhibitor PXS-5505, we demonstrate superior restoration of erythroid differentiation in hematopoietic stem and progenitor cells (HSPCs) of MN patients in 20/31 cases (65%) versus 9/31 cases (29%) treated with 5-AZA alone. This effect requires direct contact of HSPCs with bone marrow stroma components and is dependent on integrin signaling. We further confirm these results in vivo using a bone marrow niche-dependent MN xenograft model in female NSG mice, in which we additionally demonstrate an enforced reduction of dominant clones as well as significant attenuation of disease expansion and normalization of spleen sizes. Overall, these results lay out a strong pre-clinical rationale for efficacy of combination treatment of 5-AZA with PXS-5505 especially for anemic MN.

21 May 2024 in Blood Neoplasia
Verified
Journal Article
Open access
JJJohann-Christoph Jann
Johann-Christoph Jann
NSNanni Schmitt
Nanni Schmitt
ASAlexander Streuer
Alexander Streuer
QXQingyu Xu
Qingyu Xu
VRVladimir Riabov
Vladimir Riabov
DNDaniel Nowak
Daniel Nowak
• BM stroma cells of primary and xenografted MDS overexpress hematopoietic supporting factors. • The primary mesenchymal niche in MDS exhibits significant patient-level heterogeneity.

Verified
Journal Article
Open access
PDF file
QXQingyu Xu
Qingyu Xu
EAEva Altrock
Eva Altrock
NSNanni Schmitt
Nanni Schmitt
ASAlexander Streuer
Alexander Streuer
FRFelicitas Rapp
Felicitas Rapp
VRVladimir Ryabov
Vladimir Ryabov
The erythroferrone gene (ERFE), also termed CTRP15, belongs to the C1q tumor necrosis factor-related protein (CTRP) family. Despite multiple reports about the involvement of CTRPs in cancer, the role of ERFE in cancer progression is largely unknown. We previously found that ERFE was upregulated in erythroid progenitors in myelodysplastic syndromes and strongly predicted overall survival. To understand the potential molecular interactions and identify cues for further functional investigation and the prognostic impact of ERFE in other malignancies, we performed a pan-cancer in silico analysis utilizing the Cancer Genome Atlas datasets. Our analysis shows that the ERFE mRNA is significantly overexpressed in 22 tumors and affects the prognosis in 11 cancer types. In certain tumors such as breast cancer and adrenocortical carcinoma, ERFE overexpression has been associated with the presence of oncogenic mutations and a higher tumor mutational burden. The expression of ERFE is co-regulated with the factors and pathways involved in cancer progression and metastasis, including activated pathways of the cell cycle, extracellular matrix/tumor microenvironment, G protein-coupled receptor, NOTCH, WNT, and PI3 kinase-AKT. Moreover, ERFE expression influences intratumoral immune cell infiltration. Conclusively, ERFE is aberrantly expressed in pan-cancer and can potentially function as a prognostic biomarker based on its putative functions during tumorigenesis and tumor development.

1 December 2025 in JCO Clinical Cancer Informatics
Verified
Journal Article
Open access
JBJonathan Bobak
Jonathan Bobak
PSPhilipp Spohr
Philipp Spohr
SRSarah Richter
Sarah Richter
ASAlexander Streuer
Alexander Streuer
FSFelicitas Isabel Schulz
Felicitas Isabel Schulz
GKGunnar Klau
Gunnar Klau
PURPOSE: Patients with myelodysplastic syndromes (MDS) exhibit diverse disease trajectories necessitating different clinical approaches ranging from watch-and-wait strategies to hematopoietic stem cell transplantation. Existing risk scores like the IPSS-R or Endothelial Activation and Stress Index provide static risk stratification at diagnosis but do not capture evolving disease dynamics. We addressed this problem by introducing a dynamic, data-driven approach to repeatedly predict short-term mortality risks, across the patient's disease course. MATERIALS AND METHODS: We developed a machine learning model on the basis of gradient-boosted decision trees to estimate 1-year mortality risks from both longitudinal parameters from blood values and diagnosis-based features. We trained the model on a data set of patients from the MDS Registry Düsseldorf (n = 1,024) and validated it on patients from University Hospitals Heidelberg (n = 286) and Mannheim (n = 31). RESULTS: Validations on independent cohorts achieved area under the receiver operating characteristic curve scores of around 0.8 and better predictive performance for 1-year mortality compared with a diagnosis-only baseline model. The model accurately predicted mortality risks as early as within the first 90 days of diagnosis. Feature importance analysis revealed clinically plausible feature-label relations, supporting interpretability. Comparison with the IPSS-R and training on 1-year AML progression revealed the advantages and generalizability of the approach. CONCLUSION: This dynamic risk model enables continuous, individualized assessment of 1-year mortality risk in patients with MDS, offering a supplement to static scores used at diagnosis. Our results highlight the utility and importance of including longitudinal parameters in risk assessment analysis.